NCT06920004
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 19 versions: 19 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Study sites: 107 to 109
- Minor Trial sites expanded: 101 → 107 locations
- Minor Study sites: 102 to 103
- Minor Study sites: 101 to 102
- Minor Trial sites expanded: 95 → 101 locations
- Site details revised at 14 of 101 sites
- Minor Study sites: 95 to 101
- Notable Eligibility criteria expanded, about 8 words
- Trial sites expanded: 89 → 95 locations
- Secondary endpoints: details revised at 15 of 25 entries
- Minor Trial sites expanded: 82 → 89 locationsv12
- Minor Trial sites expanded: 75 → 82 locationsv11
- Minor Study sites: 73 to 75v10
- Minor Trial sites expanded: 47 → 73 locationsv9
- Minor Study sites: 46 to 47v8
- Minor Study sites: 27 to 46v7
- Minor Study sites: 10 to 27v6
- Minor Study sites: 6 to 10v5
- Minor Study sites: 4 to 6v4
- Minor Study sites: 1 to 4v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Primary completion date: May 2027 to Sep 2027
- Study completion date: May 2030 to Sep 2030
- Start date changed from estimate of May 2025 to Aug 22, 2025
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (25)
Show 20 moreShow less
Arms and interventions
During Part A, participants receive empasiprubart and a placebo resembling the IVIg treatment in this arm.
During Part A, participants receive IVIg and a placebo resembling the empasiprubart treatment in this arm.
After completion of part A, participants can proceed to part B where they receive empasiprubart (no IVIg). Participants from the empasiprubart + IVIg- placebo arm in Part A will receive empasiprubart placebo once to maintain the blind of Part A.
Biologicals: empasiprubart, IVIg
Other: empasiprubart-placebo, IVIg-placebo
Sites
109 sites in 31 countries
United States 19, Poland 12, Japan 10, France 7, Italy 7, Brazil 4, Romania 4, South Korea 4, Spain 4, Canada 3, Colombia 3, Israel 3, United Kingdom 3, Argentina 2, Austria 2, Estonia 2, Germany 2, Greece 2, Serbia 2, Slovenia 2, Turkey (Türkiye) 2, Australia 1, Czechia 1, Hungary 1, Netherlands 1, Norway 1, Portugal 1, Singapore 1, Slovakia 1, Sweden 1, Switzerland 1